Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC researchers developing the world’s largest sky-survey telescope
UNC is embarking on a bold new era of astronomical discovery with the construction of the Argus Array, a revolutionary telescope system that will be...
Wed Jul 1, 2026

These Tar Heels are working the World Cup
As the world visits North America this summer for the 2026 FIFA World Cup, some Tar Heels are helping make the historic event happen. The...
Tue Jun 30, 2026

America250 At Carolina
As the nation’s first public university, UNC-Chapel Hill has been guided for more than two centuries by a commitment to lead our state and our...
Sun Jun 28, 2026

UNC alum, former Tar Heels soccer player Jenny Chiu hosts FIFA World Cup TV series
Jenny Chiu ’17 always aimed to become a soccer star. And she has — just not in the way she imagined. As 48 countries compete...
Sat Jun 27, 2026